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Synergistic effects between the same class of antibiotics are rarely reported. Our previous
study found synergistic-like interaction between florfenicol (FFC) and thiamphenicol (TAP)
against Staphylococcus aureus. Here, the enhanced antimicrobial activity was evaluated
in 97 clinical isolates of both Gram-negative and Gram-positive bacteria. Susceptible
strains were initially identified by checkerboard microdilution assay (fractional inhibitory
concentration index [FICI] ≤0.625), followed by confirmation of synergism using the
time-kill methodology (≥2 log10 CFU/ml reduction). In all, 43% of Pasteurella multocida
tested were susceptible to the enhanced bactericidal effect. In chicken fowl cholera
models, FFC and TAP combination at much lower dosage that is correspondent to
their MIC deduction provided maximum protection in vivo. Furthermore, synergistic
combination of FFC with oxytetracycline (OTC) against Pseudomonas aeruginosa in
vitro was also demonstrated. Based on the enhanced uptake of TAP and OTC, FFC
presumably elicits enhanced antimicrobial activity in an orderly manner through alteration
of bacterial membrane permeability or efflux systems and subsequent increase of
intracellular concentration of the antibiotics used in combination. Results of ethidium
bromide accumulation assay and RNA-seq showed little evidence for the involvement
of efflux pumps in the synergy but further investigation is required. This study suggests
the potentiality of a novel combination regimen involving FFC as an initiating modulator
effective against both Gram-positive and Gram-negative bacteria depending on the
antibiotics that are combined. The observed improvement of bacteriostatic effect to
bactericidal, and the extended effectiveness against FFC-resistant bacterial strains
warrant further studies.
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INTRODUCTION
Florfenicol (FFC) and thiamphenicol (TAP), belonging to amphenicols are broad-spectrum
antibiotics commonly used in veterinary or aquacultural practice (Campa-Córdova et al., 2005;
Dowling, 2013). This kind of antibiotics binds irreversibly to the 50S ribosomal subunit preventing
protein synthesis (Dowling, 2013). TAP is a derivative of chloramphenicol (CAP) in which the
p-nitro group is replaced by a sulfomethyl group whereas FFC substitutes the hydroxyl group
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at C-3 site with a fluorine atom (Sams, 1995). Unlike CAP,
FFC, and TAP were not reported to cause aplastic anemia
(Yunis and Gross, 1975). Moreover, FFC is active at lower
concentrations than TAP and CAP against a number of bacterial
pathogens in vitro and against many CAP-resistant or TAP-
resistant strains of common infections in domestic animals (Neu
and Fu, 1980; Syriopoulou et al., 1981; Graham et al., 1988; Ueda
and Suenaga, 1995). In fact, owing to the broader spectrum of
activity and lower toxicity, FFC has been a better antimicrobial
agent replacing CAP. FFC is increasingly employed in livestock
and aquaculture for treating bacterial diseases associated with
respiratory pathogens such as Actinobacillus pleuropneumoniae,
Bordetella bronchiseptica, Mannheimia haemolytica, Pasteurella
multocida, and Streptococcus suis (Ferreira et al., 2007). In
our previous study, more than 90% of FFC was found to be
structurally degraded after 2 h of heating in boiling water.
However, the reduced FFC concentration maintained the same
antimicrobial activity against both Escherichia coli and S. aureus
due to its conversion to TAP (Franje et al., 2010). Therefore,
possible synergistic interactions between these two compounds
are hypothesized for further investigation in the present study.
Combination therapy is frequently used to provide a broader
antibacterial spectrum and to minimize toxicity as well as the
emergence of resistant bacteria (Eliopoulos and Eliopoulos,
1988). The synergism between the same class of antibiotics
was rare but not unforeseen. The use of dual β-lactam
antibiotics carbapenem (Ertapenem-Doripenem) was recently
demonstrated to be effective against KPC-producing Klebsiella
pneumoniae in both in vitro and in vivo models (Bulik and
Nicolau, 2011; Wiskirchen et al., 2013) and in clinical assay
(Ceccarelli et al., 2013). Thus, following on our initial lead
reported in 2010 (Franje et al., 2010) possible synergistic
antimicrobial activity between FFC and TAP is worthy of further
investigation. Here, the antimicrobial activity of FFC/TAP
combination in 97 clinically isolated pathogens including Gram-
negative (E. coli, Riemerella anatipestifer, Salmonella entrica, and
P. multocida, Pseudomonas aeruginosa) and Gram-positive (S.
hyicus, and S. suis) bacteria and three ATCC standard strains
were investigated. In vivo synergism against P. multocida in
chicken were evaluated. Possible mechanisms contributing to the
synergistic activity were also explored.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
A total of 97 clinically isolated strains were obtained from
the National Taiwan University Veterinary Hospital and the
Veterinary Medical Teaching Hospital of National Chung
Hsing University, Taiwan mainly within the past 5 years
(Table 1, Table S1). Three standard strains including E. coli
(ATCC25922), P. aeruginosa (ATCC27853), and S. Typhimurium
(ATCC19585) were purchased from American Type Culture
Collection (Manassas). All isolates were identified to the species
level using biochemical methods and PCR analysis. For routine
culture, E. coli, P. aeruginosa, S. hyicus, and S. entricawere grown
on trypticase soy broth (TSB). P. multocida, R. anatipestifer, and
S. suis were grown on brain heart infusion (BHI). All bacteria
were incubated at 37◦C. FFC (molecular weight: 358.21) and TAP
(molecular weight: 356.22) were purchased from Sigma-Aldrich.
Stock of TAP and FFC were dissolved in dimethylformamide
(DMF) such that the final solvent concentration in all wells was
less than 5% and showed minimal effect on bacterial growth.
Susceptibility Testing
The minimum inhibitory concentration (MIC) determinations
were performed according to the broth microdilution method
described in the Clinical and Laboratory Standard Institute
guidelines (CLSI, 2013). Briefly, serial 2-fold dilutions of FFC
or TAP in cation-adjusted Mueller-Hinton II broth (MHIIB;
Difco) or MHIIB supplemented with 5% sheep blood for S. suis
were prepared in a 96-well U bottom microtiter plate (Nunc,
ThermoScientific). Bacteria at final concentration of 5 × 105
colony-forming unit (CFU)/mL were inoculated into each well
and grown at 37◦C for 18 h. The plates were assessed by eye.
The MIC was determined to be the lowest concentration with
no visible clumps. E. coli (ATCC 25922) was used as a reference
strain for the standardization of antibiotic susceptibility. All MIC
assays in this study were done at least in triplicate.
Studies of Synergistic Effects
The synergistic interaction between FFC and TAP was assessed
by the checkerboard microdilution method using MHIIB in
triplicates in 96-well plates. Prior to the addition of bacteria,
serial dilutions of FFC and TAP were made to create different
concentration combinations in each well. In cases that the serial
dilutions go beyond the capacity of the 96-well plate, a second
plate will be used to complete the checkerboard analyses. The
bacteria at a final concentration of 5 × 105 CFU/mL was added
to each well. The fractional inhibitory concentration index (FICI)
was calculated as the sum of the MIC of each compound when
used in combination divided by the MIC of each compound used
alone (EUCAST, 2000). The obtained results were interpreted in
accordance with the BSAC recommendation as follows: synergy
(FICI≤ 0.5); no interaction (FICI > 0.5–4); antagonism (FICI >
4) (Odds, 2003).
Time-Kill Study
Time-kill studies to evaluate the killing dynamics of antibiotics
and to determine the synergistic effect of drug combination were
performed according to the guidelines by the CLSI (NCCLS,
1999). Exponentially growing cultures of tested strains were
diluted to ∼5 × 106 CFU/mL in MHIIB. Tubes containing
10 mL cultures were exposed to FFC alone at 1 × MIC (see
Table 1 for respective concentrations), or TAP alone at 1 ×
MIC, or FFC plus TAP at 1 × MIC and incubated at 37◦C.
One tube containing 10 mL culture without antibiotic was
used as a growth control. At 0, 2, 4, 8, 12, and 24 h, 20 µL
aliquots obtained from tubes were inoculated on TSA, BHI, or
blood agar for colony counts after 10-fold serial dilutions. CFU
were counted after incubation at 37◦C for 24 h. Synergy was
defined as an decrease of ≥2 log10 CFU/mL resulted by the
antibiotic combination compared to that by the more active
antibiotic alone at 24 h, while a change of <2 log10 CFU/mL
was considered indifferent (Pillai et al., 2005). Bactericidal
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TABLE 1 | In vitro inhibitory activity of florfenicol (FFC) and thiamphenicol (TAP) alone and in combination against P. multocida, S. suis, and S. hyicus.
Strains host MIC (mg/L) of antibiotics alone MIC (mg/L) in combination Fold MIC in combination FICI
FFC TAP FFC + TAP FFC OTC
Pasteurella multocida
101-035 Goose 16 512 0.5 + 256 1/32 1/2 0.531
D7 Pig 0.5 1 0.0156 + 0.5 1/32 1/2 0.531
D13 Pig 0.5 1 0.0313 + 0.5 1/16 1/2 0.563
101-086 Goose 16 1024 1 + 512 1/16 1/2 0.563
102-033 Duck 16 1024 1 + 512 1/16 1/2 0.563
A8 Pig 0.5 1 0.0625 + 0.5 1/8 1/2 0.625
D3 Pig 0.5 1 0.0625 + 0.5 1/8 1/2 0.625
D4 Pig 0.5 1 0.0625 + 0.5 1/8 1/2 0.625
0425 Pig 1 1 0.125 + 0.5 1/8 1/2 0.625
0965 Pig 32 512 4 + 256 1/8 1/2 0.625
D14 Pig 0.5 1 0.125 + 0.5 1/4 1/2 0.75
D48 Pig 0.5 1 0.125 + 0.5 1/4 1/2 0.75
101-001 Duck 0.25 512 0.0625 + 256 1/4 1/2 0.75
0037 Pig 1 2 0.25 + 1 1/4 1/2 0.75
0890 Pig 1 2 0.25 + 1 1/4 1/2 0.75
2223 Pig 64 512 16 + 256 1/4 1/2 0.75
A52 Pig 0.5 1 0.25 + 0.5 1/2 1/2 1
D1 Pig 0.5 1 0.25 + 0.5 1/2 1/2 1
D2 Pig 0.5 1 0.25 + 0.5 1/2 1/2 1
D55 Pig 0.5 0.5 0.25 + 0.25 1/2 1/2 1
1580 Pig 64 512 32 + 256 1/2 1/2 1
0104 Pig 0.5 1 0.25 + 0.5 1/2 1/2 1
0025 Pig 32 512 16 + 256 1/2 1/2 1
Streptococcus suis
CY13005-1L Pig 2 8 0.25 + 4 1/8 1/2 0.625
BL25-2 Pig 2 4 0.25 + 2 1/8 1/2 0.625
CC13002-2 Pig 0.5 2 0.125 + 1 1/4 1/2 0.75
CC13002-3 Pig 2 4 0.5 + 2 1/4 1/2 0.75
CP13021-1 Pig 2 4 0.5 + 2 1/4 1/2 0.75
CY13005-1B Pig 1 2 0.25 + 1 1/4 1/2 0.75
CY13005-3 Pig 1 2 0.25 + 1 1/4 1/2 0.75
CS13013-1 Pig 2 4 0.5 + 2 1/4 1/2 0.75
CM166-1 Pig 1 2 0.5 + 1 1/2 1/2 1
BL25-1 Pig 2 8 1 + 4 1/2 1/2 1
CY13005-2 Pig 1 2 0.5 + 1 1/2 1/2 1
CH13011 Pig 1 2 0.5 + 1 1/2 1/2 1
BL13014-3 Pig 1 2 0.5 + 1 1/2 1/2 1
Staphylococcus hyicus
CM134-2 Pig 64 1024 4 + 512 1/16 1/2 0.563
CM144-2C Pig 128 1024 32 + 512 1/4 1/2 0.75
BL11-3 Pig 4 16 1 + 8 1/4 1/2 0.75
BL11-1 Pig 4 16 2 + 8 1/2 1/2 1
BL11-2 Pig 4 16 2 + 8 1/2 1/2 1
CM144-1C Pig 8 32 8 + 32 1 1 2
activity was defined as ≥3 log10 CFU/mL reduction (99.9%
kill) in colony count from the starting inoculum. The detection
limit was 2.7 log10 CFU/mL. All CFU counting was done in
duplicate.
Ethics Statement
The animal study was approved by the Institutional Animal Care
andUse Committee at National ChungHsingUniversity (IACUC
approval No: 101-104R2). The animals were handled in strict
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accordance with the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. Experimental
animals were euthanased using 100% CO2 if they met any early
removal criteria (Humane endpoints: neural signs or cyanosis) to
minimize suffering. In addition, the possibility of animal death
without euthanasia due to acute onset of disease (septicemia) was
stated for approval by the IACUC.
Animal Study
In order to evaluate in vivo synergistic effect of antibiotic
combination, a fowl cholera model (Sarközy et al., 2002) was
performed in broiler chickens by intramuscular injection of P.
multocida. Thirty-five 3-week-old broilers (∼1 kg in weight) are
divided into seven groups with five replicates each. Chickens had
ad libitum access to feed and water throughout the experiment.
The bacterial inoculum was prepared from an overnight culture
of P. multocida (101-035) and reconstituted in phosphate-
buffered saline (PBS). A dilution solution (25% 2-pyrrolidone)
was used for resolution of TAP and FFC (5 mg/mL). All chickens
were injected intramuscularly with FFC (20 mg/kg), or TAP
(20 mg/kg), or mixed FFC/TAP (at 2.5/10 or 5 /10 mg/kg) 30
min prior to intramuscular administration of 1 × 103 CFU P.
multocida (101-035) (1 mL volume). The clinical signs were
observed every 6 h until the 3rd day.
Uptake of TAP and FFC
The method used to determine the TAP uptake was following
the assay of CAP uptake in a previous report (Burns et al.,
1985). P. multocida (101-035) was grown to mid-log phase (∼1×
109 CFU/mL) in BHI, washed once, and resuspended in 10 mL
MHIIB containing 256 mg/L TAP alone or plus 8 mg/L of FFC.
Subsequently, bacteria were incubated with shaking at 37◦C, and
500 µL was harvested at 0, 15, 30, 45, and 60 min. Bacterial
populations were counted at 0 and 60 min. The TAP and FFC
concentration in supernatant in each sample was determined by
high performance liquid chromatography (HPLC) as previously
described (Burns et al., 1985).
Cell Permeability Assay
The bacterial outer membrane permeability was measured
using 1-N-phenylnaphthylamine (NPN) as a probe according
to previous reports (Helander and Mattila-Sandholm, 2000;
Ejim et al., 2011). NPN fluoresces strongly in phospholipid
environments. Briefly, 96 well plates (black with clear bottom)
were used and each wells contained 100 µL of P. multocida (101-
035) suspension in 5mMHEPES buffer (pH 7.2), 50µL of 40mM
NPN and FFC at indicated concentration. A plate reader (Perkin-
Elmer) was used with filters of 355 nm for excitation and 460 nm
for emission and read every 10 min for 60 min at 25◦C. Results
were shown as relative fluorescent units calibrated to fluorescence
in the absence of NPN.
Uptake of OTC
The OTC uptake was evaluated via monitoring the fluorescence
enhancement of oxytetracycline according to previous reports
(Dockter et al., 1978; Ejim et al., 2011). P. aeruginosa (103-3430)
grown in 10 mL TSB to OD600 = 0.8 were harvested at 2000 g
for 10 min and then resuspended in 2.5 mL of 10 mM HEPES
pH7.2. 100 µL of drug including 256 mM OTC and FFC at
indicated concentrations was pipetted into wells (black with clear
bottom). Bacterial suspension was added at 100 µL/well and the
fluorescence read every 5 min for 60 min at 25◦C. A plate reader
(Perkin-Elmer) with filters of 405 nm for excitation and 535 nm
for emission was employed. Results were performed as relative
fluorescent units (RFU) corrected for fluorescence in the absence
of bacteria suspension.
Intracellular Accumulation Assay
The effect of FFC on the eﬄux pump was evaluated by
ethidium bromide (EtBr) accumulation using semi-automated
fluorometric method as described in previous reports (Viveiros
et al., 2008). P. multocida (101-035) was grown in BHI at 37◦C
to OD600 of 0.8, washed once and resuspended in PBS (pH 7.4)
containing 0.4% glucose to OD600 of 0.4. Aliquots of 95 µL
bacterial suspension were transfer to 0.2-mLmicrotubes and EtBr
was added at a final concentration of 2 mg/L. Rotor-Gene 3000
(Corbett Research) was employed to measure the fluorescence
using 530 nm (excitation) and 585 nm (detection) wavelengths.
Arbitrary units of fluorescence emitted by EtBr were acquired
every minute for 30 min at 37◦C.
Multistep Resistance by Serial Passage
The multistep resistance was assessed from two clinical P.
multocida isolates by serial passage in exposure to FFC, TAP, or
FFC/TAP combination. 50 mL of 1 × 108 CFU/mL P. multocida
were added to 10 mL MHIIB and incubated with sub-inhibitory
concentrations of FFC, TAP, or FFC/TAP (see Table S2 for
concentrations). The cultures were incubated at 37◦C overnight
and then were subcultured to fresh mediumwith antibiotics daily
for 12 days. MIC was determined after every 3 passages using the
microdilution method as described in Susceptibility testing.
Statistical Analysis
The bacterial populations in killing rate experiment were
analyzed by 1-way Analysis of variance (ANOVA) and Tukey’s
test for multiple comparisons. Student’s t-test was performed on
the TAP uptake data. P values of <0.05 were considered to be
statistically significant. The software GraphPad Prism 6.0 was
used for statistical analysis.
RESULTS
Combination of FFC and TAP Against
Bacterial Pathogens In vitro
Initial assessment of antibacterial effect by microdilution
checkerboard assay showed that the FFC MIC could be reduced
to 1/16 MIC (S. hyicus) and 1/32 MIC (P. multocida) in
combination with TAP at 1/2 MIC even though FICIs of all test
strains are larger than 0.5 (Table 1). Moreover, the combination
reached FICI values of <0.75 in 70% of P. multocida, 62% of
S. suis, and 50% of S. hyicus isolates tested, which could be
consider as strong additive effects if assessed according to the
European Committee for Antimicrobial Susceptibility Testing
criteria (EUCAST, 2000) for synergy (Table 1). The antibacterial
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FIGURE 1 | Synergy of florfenicol and thiamphenicol. Checkerboard
analyses showing the percentage inhibition on the combined effect of
florfenicol and thiamphenicol against (A) P. multocida, (B) S. suis, and (C) S.
hyicus. The magnitude of inhibition is shown as a heat plot.
activity against bacteria species showing ≥50% additive effect
were demonstrated as heat plots in Figure 1, which showed
concentration ranges and their percentage inhibitions on tested
strains listed in Table 1. Thirteen strains showing FICI ≤ 0.625
[one S. hyicus, two S. suis and ten P. multocida (Table 1)]
were further assessed with the time-kill study to validate if they
actually exhibited synergistic effects. At 24 h, all tested strains
exposed to FFC/TAP combination (1 × MIC) decreased more
than 2-log in CFU/mL compared to FFC or TAP alone (1 ×
MIC), suggesting the existence of synergy. The characteristic
results for representative S. hyicus, S. suis, and P. multocida
isolates are shown in Figure 2. In contrast, the combination was
ineffective against S. hyicus (CM144-1C) (FICI= 2) and the time-
kill assay showed corresponding result which was served as a
negative control (Figure 2D). Furthermore, bactericidal effects
on P. multocida, S. suis, and S. hyicus strains were observed when
exposed to the combination (Figures 2A–C).
Combination of FFC and TAP Against P.
multocida In vivo
The tested P. multocida strain 101-035 was originally isolated
from a diseased goose. A fowl cholera model in broiler chickens
by intramuscular injection of P.multocidawas employed to assess
the synergy in vivo. The challenged dose (>LD50) resulted in
100% death of chicken within 3 days. Clinical signs including
anorexia and loss of activity were observed within 24 h post-
infection for the control group and some medicated chickens.
After 24 h, chickens began to die but the survived chickens
could recover by 72 h post-infection. Subepicardial hemorrhages
and multiple necrotic spots in liver were observed in the dead
chickens. Judged by the survival rate at 72 h after infection, the
combined dosage of FFC/TAP could be reduced to as low as 5
mg/kg/+10 mg/kg (1/4 FFC +1/2 TAP recommended dose) but
still maintain 100% protection of chicken from death, indicating
a strong synergy in the protection of P. multocida infection
(Figure 3).
FFC as an Initiating Sensitizer and
Modulator of Antibiotic Uptake
To address the action mode of FFC/TAP combination, the
antimicrobial activity at which the two drugs were added in
the culture of P. multocida (101-035) at different order and
time points were assessed. The bacterial population (CFU) was
recorded at 8 h (Figure 4A). 1 × MIC of FFC added at 15, 30,
and 60 min prior to the addition of 1 × MIC of TAP exerted
the same antimicrobial activity as simultaneous addition of FFC
and TAP. In contrast, TAP added first at 30 and 60 min prior
to the addition of FFC showed reduced antimicrobial activity
suggesting that FFC contributes to the initial and critical effect
in the combination.
To further assess whether FFC promotes the entry of
TAP across cell membrane, TAP concentration in the
culture supernatants with or without FFC was quantified
by HPLC. The bacterial populations remained comparable
between TAP and TAP/FFC treatment over the 60-min
incubation period. The uptake of TAP was significantly
increased by 3 folds (from 4 to 13%) at 60 min when FFC
(8 mg/L, final concentration) was present in the culture
(Figure 4B). On the other hand, there was no significant
difference in the uptake of FFC in the absence or presence
of TAP (Figure 4C). To further assess whether FFC affect
the outer membrane permeability, 1-N-phenylnapthylamine
was employed as a fluorescent probe and found that FFC
increased the membrane permeability of P. multocida
(Figure 4D).
Combination of FFC and OTC Showed
Enhanced Antibacterial Activity Against P.
aeruginosa
To elucidate whether the enhancement of antibiotic entrance by
FFC was specific to amphenicols, we further studied the uptake
of OTC in the presence of sub-MIC level of FFC in P. aeruginosa
(103-3430) via monitoring of the fluorescence enhancement of
OTC in the cell. A dose-dependent increase of OTC by FFC
was observed (Figure 5). The results correspond well to the
checkerboard assay, FFC in combination with oxytetracycline
(OTC) exhibited synergistic effect (FICI ≤ 0.5) against 4/9 (44%)
of P. aeruginosa in vitro (Table 2).
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FIGURE 2 | Time-kill curves of combinations of florfenicol (FFC) and thiamphenicol (TAP) against (A) P. multocida (101-035), (B) S. suis (CY13005-1L),
(C) S. hyicus (CM134-2), and (D) a non-synergistic strain, S. hyicus (CM144-1C) which serves as a negative control. Refer to Table 1 for strain MIC data.
Each point represents the mean of duplicate determinations. The detection limit (dotted line) was 2.7 log10 CFU/mL.
FIGURE 3 | Florfenicol (FFC)/thiamphenicol (TAP) combination protects
broiler chickens from P. multocida infection. Five groups of five broiler
chickens challenged with 103 CFU of P. multocida (101-035) and the mortality
was recorded every 6 h until 72 h post infection.
The Effect of FFC on the Efflux System of P.
multocida
To investigate possible role of eﬄux systems in FFC modulation,
the semi-automated fluorometric method was used. In contrast
to the eﬄux inhibitor, verapamil, which at 1/2 MIC significantly
increased accumulation of EtBr in P. multocida (101-035);
FFC at 4, 8, and 16 mg/L only resulted in insignificant
increase of EtBr accumulation inside the cells (Figure 6).
A marginal accumulation of EtBr was observed and might
be attributed to the increase of membrane permeability or
the inhibition of a minor eﬄux pump. To further elucidate
whether the expressions of eﬄux pumps are affected by FFC,
the transcriptome of P. multocida (101-035) growing in the
presence and absence of FFC at sub-MIC levels were compared
using Illumina RNA-seq. Based on the general criterion of
gene expression (fold change ≤ 2 or > 2 at P values <
0.02); out of the 2190 open reading frames (ORFs) predicted
in the P. multocida genome, the sub-MIC FFC treatment
caused 74 (3.3%) ORFs upregulated and 65 (3.0%) ORFs
downregulated (Table S3). However, no eﬄux pump-related gene
was significantly up or down regulated in the sub-MIC FFC
treatment (Table S3).
Assessment of FFC/TAP Resistance
Induction in Sub-Inhibitory Concentrations
by Serial Passage of P. multocida
Recent studies revealed that exposure to sub-MIC antibiotic
has an important role on the evolution of antibiotic resistance
(Baquero et al., 1998; Andersson and Hughes, 2014). To
address whether the combination of FFC and TAP in sub-
inhibitory concentration may accelerate the development of
resistance in P. multocida, the emergence of multistep resistance
were evaluated by serial passage of bacteria every day for 12
days in sub-inhibitory concentration level (See Table S2 for
concentrations). After 12 days of passage, the MIC of FFC/TAP
combination in susceptible strain was not changed when
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FIGURE 4 | Facilitated uptake of thiamphenicol (TAP) by florfenicol (FFC). (A) Killing rates of florfenicol (FFC) and thiamphenicol (TAP) in different mixing times
against P. multocida. Time indicates minutes FFC was added prior to (FFC→TAP) or after (TAP→FFC) TAP addition. (-) represented the control culture without addition
of antibiotics. Bacteria populations were counted at 24 h and compared using one way ANOVA and Tukey’s test for multiple comparisons. P values of less than 0.05
were considered significant. Statistical significance is presented as **P < 0.01, or *P < 0.05. (B) Uptake of TAP (depletion in medium) presented as a percentage of
the initial concentration: 256 mg/L on P. multocida. The concentration of FFC was 8 mg/L. The data shown are the means ± SE of three independent experiments
and were analyzed using Student’s t-test. (*P < 0.05). (C) Uptake of FFC presented as a percentage of the initial concentration: 8 mg/L on P. multocida. The
concentration of TAP was 256 mg/L. (D) Permeability of P. multocida was evaluated by measuring the 1-N-phenylnaphthylamine (NPN) at 10 min after FFC treatment
at indicated concentration. The data shown are the average of triplicate experiments. The deviations between triplicate data point were <5%.
FIGURE 5 | Florfenicol (FFC) enhances the uptake of oxytetracycline in
P. aeruginosa. Concentration of oxytetracycline was 128 mg/L, and FFC
concentration was 0, 1, and 8 mg/L. Averages of triplicate experiments are
shown.
grown with single antibiotic or combination (Figures 7A–C).
Interestingly, unlike exposure to single antibiotic, exposure
to FFC/TAP combination resulted in 2-fold decrease in
FFC and TAP MIC (Figure 7C). Likewise, the MIC of
FFC/TAP combination in resistant strain was not increased
when grown in either FFC or the FFC/TAP combination
(Figures 7D,F). However, the MICs of FFC, TAP, and FFC/TAP
combination elevated 2 folds when exposed to TAP for 12 days
(Figure 7E).
DISCUSSION
Florfenicol is mainly administrated to combat bovine respiratory
infections, it showed a broad spectrum of activity against Gram-
negative bacteria such as E. coli, K. pneumoniae, Proteus valgaris,
and P. multocida and also some Gram-positive bacteria such as S.
aureus (Neu and Fu, 1980) and S. suis (Ferreira et al., 2007). The
current results showed general agreement with the published data
in antibacterial spectrum. Although, FFC was effective against P.
multocida, S. suis, and S. hyicus, its analog TAP was shown to be
much less effective than FFC (Table 1) and virtually not effective
in practice. Therefore, the significant dose reduction by 75% in
FFC and 50% in TAP and still maintained the same antimicrobial
effectiveness both in vitro and in vivo has made the combination
a notable case worth pursuing.
The synergism between the same class of antibiotics seemed
unforeseeable. In fact, it was first observed as an incidental
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TABLE 2 | In vitro inhibitory activity of florfenicol (FFC) and oxytetracycline (OTC) alone and in combination against P. aeruginosa.
Strains host MIC (mg/L) of antibiotics alone MIC (mg/L) in combination Fold MIC in combination FICI
FFC OTC FFC + OTC FFC OTC
ATCC27853 256 32 32 + 16 1/8 1/2 0.625
103-3430 Rabbit 128 32 32 + 8 1/4 1/4 0.500
103-3713 Rabbit 256 32 64 + 8 1/4 1/4 0.500
27825 Rabbit 256 32 64 + 8 1/4 1/4 0.500
103-303 Rabbit 256 64 64 + 16 1/4 1/4 0.500
103-9432 Dog 512 64 128 + 32 1/4 1/2 0.75
103-1597 Dog 128 64 32 + 32 1/4 1/2 0.75
103-0044 Rabbit 256 1024 64 + 512 1/4 1/2 0.75
103-3190 Dog 512 64 256 + 32 1/2 1/2 1
FIGURE 6 | Accumulation of ethidium bromide by P. multocida in the
addition of increasing concentrations (mg/L) of florfenicol (FFC) at
37◦C. Verapamil (VP), a well-known efflux pump inhibitor, was added at 400
mg/L (1/2 MIC). The experiment was repeated three times with similar results.
finding in a study of heat stability of antibiotics. It was
then assessed by multiple microbiological evaluations that are
accepted as standard measures for identification of synergistic
activities. The checkerboard method was first applied to assess
the interaction of FFC and TAP. In a 2-fold dilution process,
although the FFC MIC of certain strains could be reduced to
1/32 of the original, the MIC reduction for TAP could only
reach 1/2, which rendered all FICIs to be above 0.5 (additivity
by definition). In order to elucidate whether the combination
reaches synergistic effect (FICI ≤ 0.5), the giant checkerboard
(Horrevorts et al., 1987; Hsieh et al., 1993) was then employed for
further dilution of TAP to between 1/2 MIC and 1/4 MIC. The
results revealed that the combination actually exerted a strong
synergistic effect (FICI ≤ 0.5) on 16/21 (77%) of the strains
whose FICI was originally between 0.5 and 0.625 (Table S4).
The synergism was also confirmed by another in vitro method,
time-kill study. The methods employed to assess the synergism
including checkerboard and time-kill assay have been compared
in several reports (Weinstein et al., 1975; Norden et al., 1979;
Bayer and Morrison, 1984; White et al., 1996; Rose et al., 2013).
Certain studies revealed that the time-kill assay is more reliable
in the prediction of in vivo synergism (Bayer and Morrison,
FIGURE 7 | Development of resistance after serial exposure to
florfenicol (FFC), thiamphenicol (TAP) and FFC+TAP. Serial passage of P.
multocida (0425) (A–C) and (101-035) (D–F) exposed to sub-MIC levels of
florfenicol (FFC) (A,D), thiamphenicol (TAP) (B,E), and FFC+TAP (C,F). MIC of
each point was determined at least in triplicates. The experiment was repeated
three times with similar results.
1984; Chadwick et al., 1986) and exhibited synergy with higher
frequency than did the checkerboard (Norden et al., 1979; Bayer
and Morrison, 1984; White et al., 1996). In current study, we also
observed the synergism with higher frequency in the time kill
assay.
Interestingly, Gram-positive species, S. hyicus and S. suis,
showed higher frequency of additive effect and synergistic effects
in some strains in the initial checkerboard screening, suggesting
that this combination mainly affect Gram-positive bacteria.
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Gram-negative bacteria are known to contain a surrounding
outer membrane severing as a barrier to nonpolar compound or
certain antibiotics (Nikaido and Nakae, 1979; Nikaido and Vaara,
1985). Therefore, it is possible that the FFC/TAP combination
falls in this category and was obstructed by the outer membrane
and thereby exhibited less synergistic effect. Nevertheless, among
the five Gram-negative species tested, P. multocida showed high
percentage of susceptibility to FFC/TAP interaction. This might
be explained by the high permeability of outer membrane for
nonpolar compounds (Watt et al., 2003; Ellison and Champlin,
2007) in this species, which render it more susceptible to
distinct hydrophobic antimicrobial agents despite that the cell
envelope ultrastructure of P. multocida is characteristically a
Gram-negative bacteria (Hart and Champlin, 1988). Results
from Figures 4A,B showed that the effect of FFC preceded TAP
(not in reversed order) in the exertion of synergistic activity,
likely through the increased membrane permeability (indicated
by NPN) that resulted in significantly increased (>3 folds)
intracellular TAP concentration (Figure 4D). Therefore, it is
feasible to assume that FFC/TAP combination works in an
orderly manner, in which FFC acted as an initiating sensitizer
to enhance the entrance of cognate antibiotics (such as TAP)
through the bacterial cytoplasm. The role of FFC as an initiator
(enhancer) was further demonstrated in its combination to
other class of antibiotic OTC. Notably, FFC by itself is not
an effective drug against P. aeruginosa, most strains of P.
aeruginosa were intrinsically resistant to CAP due to very
low permeability of their outer membrane and the efforts of
eﬄux pumps (Angus et al., 1982; Li et al., 2015). However,
FFC in combination with OTC showed synergistc effect against
P. aeruginosa due to enhancement of OTC uptake (Table 2,
Figure 5). Our preliminary investigation also revaled that sub-
MIC FFC is able to cripple P. aeruginosa in swimming motility
assay (data not shown), suggesting that FFC might affect the
flagellar function via abolishing the proton motive force to
triger the uptake of OTC (Paul et al., 2008). Therefore, the
latter result may represent a different type of combinational
antibacterial effect. Nevertheless, both results supported that FFC
acts as an initiating modulator of membrane permeability that
allows increased uptake of multiple antibiotics by susceptible
Gram-negative bacteria.
In addition to the permeability barrier of outer membrane,
the multidrug pumps (eﬄux pumps) usually contribute the
antibiotic resistance in synergy with outer membrane (Li et al.,
2015). Thus, the accumulation of EtBr was employed to address
whether FFC act as an eﬄux pump inhibitor and RNA-seq
was used to evaluate the expression of eﬄux pump-related
genes. Our data showed slight accumulation of EtBr as FFC
concentration is increased may reflect minor inhibitory effect
of eﬄux pump such as resistance-nodulation-division (RND)-
type transporter. However, transcriptomic analysis performed
in the presence or absence of sub-MIC FFC revealed that the
expression of eﬄux pump-related genes was not significantly
altered. So far, whether FFC serves as an eﬄux pump inhibitor
is not confirmed and requires more investigation. This study
raises an interesting observation that FFC acts as a modulator
not only promote uptake of OTC, but also TAP even though
they are analogs. Further investigations are required to address
the mechanism, including the reverse transcription-PCR to
validate the observed gene expression. In addition, Blickwede
et al. demonstrated that sub-MIC of FFC results in a distinct
thickening of the staphylococcal cell wall andmight cause cellular
disruption due to a compression of the protoplast (Blickwede
et al., 2004). Thus, for Gram-positive bacteria, another plausible
hypothesis to support the synergistic effect could be that the
FFC at sub-MIC concentration condenses the bacterial protoplast
leading to higher intracellular TAP concentration. Further,
studies investigating whether FFC predisposition also synergizes
with other classes of antibiotics against Staphylococcus spp.
or other Gram-positive bacteria may shed more light on this
hypothesis.
P. multocida is the causative agent of primary infections
in the domestic animals as well as opportunistic infections in
humans (Wilson and Ho, 2013). Intramuscular injection with
P. multocida to cause fowl cholera was demonstrated as a
reliable and reproducible model (Sarközy et al., 2002). In the
chicken model, a FFC-resistant strain but showing significant
susceptibility to the FFC/TAP combination in vitro was used.
The results indicated that the antimicrobial activity was dose-
dependent after FFC/TAP co-administration, while 80% of
challenged-chicken survived at the recommended FFC dose
(20 mg/kg), the co-administration at lower dosage was able
to protect 100% chickens, suggesting better efficacy. It is also
worth noting that the combination restores a drug (TAP) that
is not very effective when used alone. Interestingly, the ratio
of the dosage combination was proportional to their in vitro
MIC results. Whether or not this ratio carries any mechanistic
importance remains to be elucidated, but this combination
significantly reduced the amounts of drugs administered, and it
is plausible that a favorable pharmacokinetic behavior leading
to less unwanted tissue residues and side effects are expected
and the cost for treatment could be largely reduced with this
combinational therapy.
In summary, this study is the first to report FFC as
a possible synergistic antibacterial modulator to multiple
antibiotic classes and is effective against both Gram-positive
and Gram-negative bacteria depending on the antibiotics in
combination. The antibacterial spectrum, in vitro bactericidal
activities, in vivo effectiveness, and mechanisms of action were
systematically investigated using combination with another
amphenicol TAP as an example. When used in sub-MIC levels
(usually 1/4 of its original MIC), FFC presumably exhibited
synergistic antibacterial activity through alteration of bacterial
membrane permeability and subsequent increase of intracellular
concentration of the antibiotics used for combination. The eﬄux
pumps commonly responsible for reduced therapeutic effect and
the development of antibacterial resistance were yet to be proven
in the mechanism based on EtBr accumulation assay and RNA
sequencing. The current discovery provided abundant evidence
to support further development of drug combinations involving
FFC as an initiating modulator.
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